Collegium Announces FDA Tentative Approval for Xtampza(TM) ER, a Novel Abuse-Deterrent Analgesic for Chronic Pain

09 November, 2015

Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announces that the United States Food and Drug Administration (FDA) has granted tentative approval to the Company’s New Drug Application (NDA) for Xtampza™ ER (oxycodone) extended-release capsules.